#1 Clinical Trials Search in Europe

Emedastine

This article explores the use of Emedastine Difumarate Eye Drops in clinical trials for the treatment of allergic rhinitis. The study focuses on comparing the efficacy of allergen-specific immunotherapy with conventional drug treatments, including Emedastine, in managing symptoms of seasonal allergic rhinitis caused by Artemisia pollen.

Table of Contents

What is Emedastine?

Emedastine, specifically Emedastine Difumarate, is a medication used in the form of eye drops to treat symptoms of allergic rhinitis[1]. Allergic rhinitis is a condition where your nose becomes inflamed due to an allergic reaction, often causing symptoms like sneezing, runny nose, and itchy eyes.

How is Emedastine Used?

Emedastine Difumarate is administered as eye drops. In the clinical trial described, it was used once a day as needed to relieve allergy symptoms[1]. However, always follow your doctor’s instructions on how often to use the medication.

Conditions Treated by Emedastine

Emedastine is primarily used to treat symptoms associated with allergic rhinitis. This condition is described in the clinical trial as “a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens.”[1] In simpler terms, it’s an allergic reaction in your nose caused by things like pollen, dust, or pet dander.

Clinical Trial Information

A clinical trial (NCT05318157) was conducted to study the effectiveness of allergen-specific immunotherapy for allergic rhinitis caused by Artemisia pollen. While Emedastine was not the main focus of this study, it was used as part of the treatment regimen[1].

The trial involved 150 subjects with allergic rhinitis caused by Artemisia pollen. Participants were divided into two groups: one receiving immunotherapy and another receiving conventional drug treatment, which included Emedastine Difumarate Eye Drops[1].

Other Treatments Used in Combination

In the clinical trial, Emedastine Difumarate Eye Drops were used in combination with other medications to manage allergy symptoms. These included:

  • Clarityne: An antihistamine that helps reduce allergy symptoms like sneezing and itching
  • Rhinocort: A nasal spray containing corticosteroids to reduce inflammation in the nose

These medications were permitted to be used once a day, as needed, to relieve allergy symptoms[1].

Effectiveness of Emedastine

While the clinical trial doesn’t provide specific information about the effectiveness of Emedastine alone, it was included as part of the conventional drug treatment for allergic rhinitis. The study measured several outcomes to assess the effectiveness of the treatments, including:

  • Changes in symptom scores
  • Quality of life improvements
  • Daily medication usage
  • Combined symptom and medication scores

These measurements were taken at various points throughout the study, including at baseline, during the high pollen seasons for three years, and at the end of the two-year treatment period[1]. The results of these measurements would help determine how effective the treatment regimen, including Emedastine, was in managing allergic rhinitis symptoms.

Aspect Details
Study Type Randomized, Open-label, Multicentered trial
Participants 150 subjects with allergic rhinitis caused by Artemisia pollen
Treatment Groups 1. Sublingual Immunotherapy group
2. Drugs treatment group (including Emedastine Difumarate Eye Drops)
Emedastine Usage Once daily, as needed for symptom relief
Primary Outcomes 1. Change in symptom scores
2. Change in quality of life scores
Secondary Outcomes 1. Daily medication score
2. Combined symptom and medication score
3. Health economics evaluation
4. Adverse events
5. Biomarker changes
6. Cytokine expression changes
7. Nasal cavity measurements
8. IgE level changes
Study Duration 3 years with multiple assessment points

FAQ

  • What is the purpose of using Emedastine Difumarate Eye Drops in this clinical trial? Emedastine Difumarate Eye Drops are used as part of the conventional drug treatment for allergic rhinitis symptoms, particularly for managing ocular symptoms such as eye itching and watery eyes.
  • How often are Emedastine Difumarate Eye Drops administered in the trial? According to the trial protocol, Emedastine Difumarate Eye Drops are administered once a day, as needed, to relieve allergy symptoms.
  • What other medications are used alongside Emedastine Difumarate Eye Drops? In addition to Emedastine Difumarate Eye Drops, the conventional drug treatment group also receives Clarityne (an antihistamine) and Rhinocort (a nasal corticosteroid).
  • How is the effectiveness of the treatment measured in the trial? The trial measures effectiveness through changes in symptom scores, quality of life questionnaires, medication scores, and various biomarkers. It also assesses nasal cavity volume and airway resistance.
  • How long does the clinical trial last? The clinical trial spans over three years, with assessments made at baseline and during the high pollen seasons of the first, second, and third years.

Ongoing Clinical Trials on Emedastine

  • Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Germany

Glossary

  • Allergic Rhinitis (AR): A non-infectious inflammatory disease of the nasal mucosa caused by an allergic reaction to allergens, resulting in symptoms like sneezing, runny nose, and itchy eyes.
  • Allergen-specific immunotherapy (AIT): A treatment method that involves exposing patients to gradually increasing amounts of an allergen to reduce their sensitivity and allergic symptoms over time.
  • Emedastine Difumarate: An antihistamine medication used in eye drop form to relieve ocular symptoms of allergic reactions, such as itching and watery eyes.
  • Visual Analogue Scale (VAS): A measurement tool used to assess the severity of symptoms on a scale from 0 (no symptoms) to 10 (very severe symptoms).
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): A survey that measures how allergic rhinitis affects a patient's quality of life across various aspects, including symptoms and daily activities.
  • Combined Symptom and Medication Score (CSMS): A score that combines daily symptom severity with medication usage to provide a comprehensive assessment of allergy control.
  • Immunoglobulin E (IgE): An antibody that plays a crucial role in allergic reactions, with higher levels often indicating increased sensitivity to allergens.
  • Acoustic Rhinometry: A technique used to measure the geometry of the nasal cavity and assess nasal congestion.
  • Rhinomanometry: A method used to measure nasal airway resistance and assess nasal breathing difficulties.

References

  1. https://clinicaltrials.gov/study/NCT05318157